GW Pharma Sells for Billions; Psychedelic Company Following Similar Path
Jazz Pharmaceuticals paying $7.2 billion for cannabis drug maker GW Pharma has investors looking at early-stage psychedelic companies.
- Jazz Pharmaceuticals paying $7.2 billion for cannabis drug maker GW Pharma has investors looking at early-stage psychedelic companies.
- Tryp Therapeutics is one of only a handful of companies moving into Phase 2 clinical trials with a psychedelic compound.
- GW was a true trendsetter with its Epidiolex (cannabidiol) for controlling seizures in rare forms of epilepsy.
- A similar trend is underway with psychedelics, which are already benefiting from the path carved by cannabis drug development pioneers such as GW.